EPTIS
BAM Logo

CRC - Colorectal Carcinoma

[CRC - Kolorektální karcinom]

EPTIS factsheet 645488 | Last revision 2024-11-08 | URL: https://www.eptis.bam.de/pts645488 https://www.eptis.bam.de/pts645488

PT provider
PT provider SEKK SEKK
Based in Czechia
Language(s) English, Czech
Remarks Complete EQA Plan is freely available here: https://www.sekk.cz/eqa/EQA_1.htm
Keywords
Product groups Health care / medical devices
Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Every participant receives 3 sections of each primary sample (6 µm thick). One section is to be used for hematoxylin-eosin (HE) staining and the remaining 2 sections for DNA isolation and mutation detection. -
1 set containing 15 unstained FFPE sections obtained from 5 primary samples (invasive colorectal adenocarcinomas). Detection of KRAS, NRAS, BRAF genes mutations clinically relevant to anti-EGFR therapy Participant's routine method
Aims of the PT scheme
Target group of participants medical laboratories
Linked to specific legislation / standards ISO 17043
Additional, subsidiary aims
Number of participants 50
Accredited or otherwise reviewed by a 3rd party

Approved by European Society of Pathology (ESP)

Operation is commissioned / requested by
Fees and frequency
Participation fee Complete price list you can find in the document EQA Plan. It is freely available at our web: https://www.sekk.cz/index_1.htm
Regularly operated Yes (2 round per year)
Year of first operation 2019
Contact details of the PT provider
Provider Contact person
SEKK
B35
53001 Pardubice
Czechia

Phone: +420 466530230
Fax:
Web: http://www.sekk.cz http://www.sekk.cz
Ing. Marek Budina
Phone: +420 466530230
Fax:
Email: sekk@sekk.cz sekk@sekk.cz
If you find any mistakes please contact the responsible EPTIS coordinator in Czechia, Ms Simona Klenovská. Ms Simona Klenovská.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5